Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports.
Thalidomide, a racemic glutamic acid analogue, was first developed in 1954 and subsequently marketed in Europe, Australia and Canada as a sedative and anti-emetic. It was approved by the Food and Drug Administration (FDA) in the USA in 1998 for the treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and suppression of the cutaneous manifestations of ENL recurrences. It is a good choice for management in patients who are dependent on corticosteroids. Common side effects of thalidomide are teratogenicity, peripheral neuropathy, sedation and constipation. We report 4 cases of Hansen's disease with recurrent ENL who were adequately managed on thalidomide. On sudden withdrawal of thalidomide, they relapsed with severe type 2 reaction including necrotic ENL.
Rattan
R
R
Department of Dermatology, Venereology and Leprology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
Shanker
V
V
Tegta
G R
GR
Verma
G K
GK
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004893:Erythema Nodosum / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007917:Leprostatic Agents / Q000008:administration & dosage*; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D012008:Recurrence; D012867:Skin / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D007917:Leprostatic Agents; D013792:Thalidomide